Prof. Dr. Frank Dörje

Naturwissenschaftliche Fakultät Lehrstuhl für Pharmazeutische Technologie und Biopharmazie Apotheke des Universitätsklinikums Professur für Molekulare und Klinische Pharmazie

Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study (2021) Schlichtig K, Dürr P, Dörje F, Fromm M Journal article Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab (2021) Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Journal article Medication safety in intravenous therapy: A compatibility study of clonidine with drugs frequently used in intensive care (2021) Koller AK, Krebs S, Dörje F Journal article Medication safety in intravenous therapy: A compatibility study and analysis of reaction products of dihydralazine and metamizole (2020) Koller AK, Fischer O, Krebs S, Heinrich M, Dörje F Journal article Medication Safety in Patients Treated with New Oral Antitumor Agents: A Prospective, Randomized Investigation on the Impact of Intensified Clinical Pharmaceutical/Clinical Pharmacological Care on Patient Safety and Well-Being (AMBORA). Supported by the German Cancer Aid (70112447) within the Comprehensive Cancer Center Erlangen-EMN (2020) Schlichtiq K, Duerr P, Fromm M, Dörje F Conference contribution Arzneimitteltherapieanamnese in Zeiten von COVID-19: Nutzung von Krankenkassendaten zur Vermeidung von Medikationsfehlern (2020) Dörje F, Grandt D, Picksak G, Klaas C Journal article, Review article Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study (2020) Fischer S, Mesfin SE, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Conference contribution New Oral Anti-Cancer Drugs and Medication Safety (2019) Schlichtig K, Duerr P, Dörje F, Fromm M Journal article, Review article Medication safety of new oral antitumor agents: a randomized trial on the impact of a clinical pharmacological / pharmaceutical intervention on drug-related problems and patient safety (2019) Schlichtig K, Duerr P, Dörje F, Fromm F Conference contribution Medication safety in patients treated with new oral antitumor agents: a prospective, randomized investigation on the impact of intensified clinical pharmaceutical/ clinical pharmacological care on patient safety and well-being (AMBORA-Study - supported by the German Cancer Aid (70112447)) (2019) Duerr P, Schlichtig K, Dörje F, Fromm M Conference contribution